Journal Article

Nevirapine Levels after Discontinuation of Rifampicin Therapy and 60-Week Efficacy of Nevirapine-Based Antiretroviral Therapy in HIV-Infected Patients with Tuberculosis

Weerawat Manosuthi, Kiat Ruxrungtham, Sirirat Likanonsakul, Wisit Prasithsirikul, Yaowarat Inthong, Thanongsri Phoorisri and Somnuek Sungkanuparph

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 44, issue 1, pages 141-144
Published in print January 2007 | ISSN: 1058-4838
Published online January 2007 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/510078
Nevirapine Levels after Discontinuation of Rifampicin Therapy and 60-Week Efficacy of Nevirapine-Based Antiretroviral Therapy in HIV-Infected Patients with Tuberculosis

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study. After discontinuation of rifampicin therapy, mean nevirapine levels (±; standard deviation) increased from 5.4 ±; 3.5 mg/L to 6.4 ±; 3.4 mg/L (P = .047), but no nevirapine-related adverse events occurred. There was no statistically significant difference in 60-week antiviral efficacy between these patients and patients receiving nevirapine-based antiretroviral therapy alone (P > .05).

Journal Article.  2168 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.